Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Year:
      2020
    • Author-Supplied Keywords:
      Biomarker
      Gastric cancer
      Lnc-LIFR-AS1
      Prognosis
    • Abstract:
      OBJECTIVE: Abundant evidence has demonstrated that long non-coding RNAs (lncRNAs) play key roles in the development of human neoplasms. A novel cancer-related lncRNA, leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1), has been reported to be under-expressed in breast cancer and associated with poor prognosis, but its significance in gastric cancer (GC) remains to be determined. Therefore, we assessed the prognostic and diagnostic value of LIFR-AS1 in GC. PATIENTS AND METHODS: Quantitative RTPCR assay was used to detect the expression levels of LIFR-AS1 in GC tissues and adjacent normal tissues. The correlation between LIFR- AS1 expression and clinicopathological features was analyzed by Pearson's 2-test. The disease- free survival and overall survival rates of GC patients were calculated by the Kaplan-Meier method. Cox regression analysis was used to assess factors related to survival. RESULTS: In this study, levels of LIFR-AS1 were significantly higher in GC tumor samples relative to adjacent normal tissue samples. A ROC analysis suggested LIFR-AS1 expression could be reliably used to differentiate between normal and GC tumor tissue. In addition, elevated LIFR-AS1 expression was positively correlated with more advanced and aggressive GC features, such as larger tumor size, lymphatic metastasis, and more advanced TNM stage. Survival analyses revealed that elevated LIFR-AS1 expression was correlated with worse overall survival and disease-free survival. Multivariate analysis further confirmed the relevance of LIFR-AS1 as an independent predictor of GC patient outcomes. CONCLUSIONS: In summary, these results indicate that the lncRNA LIFR-AS1 is a promising prognostic indicator in GC patients. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of European Review for Medical & Pharmacological Sciences is the property of Verduci Editore and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      11283602
    • Accession Number:
      143487103
  • Citations
    • ABNT:
      WANG, H.-F. et al. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. European Review for Medical & Pharmacological Sciences, [s. l.], v. 24, n. 10, p. 5378–5384, 2020. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103. Acesso em: 23 set. 2020.
    • AMA:
      WANG H-F, LV J-Q, LI H-H, WANG W, LIN F-Q. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. European Review for Medical & Pharmacological Sciences. 2020;24(10):5378-5384. Accessed September 23, 2020. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103
    • APA:
      WANG, H.-F., LV, J.-Q., LI, H.-H., WANG, W., & LIN, F.-Q. (2020). High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. European Review for Medical & Pharmacological Sciences, 24(10), 5378–5384.
    • Chicago/Turabian: Author-Date:
      WANG, H.-F., J.-Q. LV, H.-H. LI, W. WANG, and F.-Q. LIN. 2020. “High Long Non-Coding LIFR-AS1 Expression Correlates with Poor Survival in Gastric Carcinoma.” European Review for Medical & Pharmacological Sciences 24 (10): 5378–84. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103.
    • Harvard:
      WANG, H.-F. et al. (2020) ‘High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma’, European Review for Medical & Pharmacological Sciences, 24(10), pp. 5378–5384. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103 (Accessed: 23 September 2020).
    • Harvard: Australian:
      WANG, H-F, LV, J-Q, LI, H-H, WANG, W & LIN, F-Q 2020, ‘High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma’, European Review for Medical & Pharmacological Sciences, vol. 24, no. 10, pp. 5378–5384, viewed 23 September 2020, .
    • MLA:
      WANG, H. F., et al. “High Long Non-Coding LIFR-AS1 Expression Correlates with Poor Survival in Gastric Carcinoma.” European Review for Medical & Pharmacological Sciences, vol. 24, no. 10, May 2020, pp. 5378–5384. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103.
    • Chicago/Turabian: Humanities:
      WANG, H.-F., J.-Q. LV, H.-H. LI, W. WANG, and F.-Q. LIN. “High Long Non-Coding LIFR-AS1 Expression Correlates with Poor Survival in Gastric Carcinoma.” European Review for Medical & Pharmacological Sciences 24, no. 10 (May 15, 2020): 5378–84. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103.
    • Vancouver/ICMJE:
      WANG H-F, LV J-Q, LI H-H, WANG W, LIN F-Q. High long non-coding LIFR-AS1 expression correlates with poor survival in gastric carcinoma. European Review for Medical & Pharmacological Sciences [Internet]. 2020 May 15 [cited 2020 Sep 23];24(10):5378–84. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edo&AN=143487103